Kyowa Kirin pulls the plug on drug development for successor to Parkinson's drug Nourianz
Three years after Japan’s Kyowa Kirin secured FDA approval for an add-on therapy to levodopa in Parkinson’s, the company has scrapped its potential successor.
Kyowa Kirin issued a short statement Friday on the new development after conducting two Phase II studies in Japan: an early Phase II with 175 participants finished in 2017, and a Phase IIb with 502 participants that concluded in 2020. The company said those studies provided a signal the drug could be potentially effective in Parkinson’s by itself and as a combination therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.